A new drug compound could combat tough-to-treat melanoma
Melanoma is commonly caused by the damaging effects of ultraviolet light—from sources like sunlight and tanning beds—on the DNA of skin cells. This UV damage can activate genes that encourage precancerous cells to further mutate into full-blown skin cancer. At the same time, UV damage can turn off other genes that would normally prevent tumor growth. With enough wrongly flipped switches, cancer can flourish. And melanoma is certainly flourishing. This year alone, 96,480 new instances of melanoma will be diagnosed in the United States and 7,230 Americans will die from the disease.
With so many people affected by melanoma, scientists are on the hunt for better ways to screen for melanoma risk and treat the most lethal types of skin cancer. One particularly voracious type of melanoma, caused by mutation of a gene called NRAS (which instructs cells to produce a protein of the same name, NRAS), drives 25 percent of skin cancers.
“There are immunotherapies and targeted therapies that have shown huge improvements for patients with melanoma,” said Rutao Cui, a Boston University School of Medicine professor of pharmacology and dermatology. “However, for patients with NRAS mutations, they don’t have very useful or very effective treatment strategies.”
Now, an international research team led by Cui has discovered a new way to stop the progression of melanoma by NRAS mutations with the flip of a genetic switch. Their findings were published January 31, 2019, in Cell.
Inside our bodies, proteins like NRAS play the role of dominoes, interacting with one another to switch other important gene activities on or off. The researchers set out in search of a way to interrupt the process in which mutated NRAS can instigate the growth of skin cancer. Since targeting the NRAS gene—just one of several dominoes in this type of skin cancer pathway—has proven to be so difficult, the researchers were determined to find another approach.
For NRAS to trigger cancer development, it first needs to be activated by another protein in the body. Until now, it’s been unknown exactly which protein is responsible for activating NRAS. But after testing the effect of several different proteins on the activity of NRAS, the team zeroed in on a likely culprit, a protein by the name of STK19.
STK19 is not a newly discovered protein in its own right, but its purpose has not been known until now. Cui’s team found that STK19 appears to work as an “on” switch for NRAS—activating production of NRAS proteins which, in turn, trigger the toppling of several other genetic dominoes downstream.
The researchers also found that, unlike NRAS, they could disable the STK19 gene and greatly diminish its ability to set the skin cancer sequence in motion.
Together, the team designed a new drug compound to shut down the effect of STK19 on NRAS. Then, testing its effect on skin cells cultured in petri dishes and in animal models, they proved that their compound can block NRAS activation and prevent melanoma from developing.
Cui says that this result is exciting not just for melanoma, but for other cancers as well. While the relationship between STK19 and NRAS may be particular to skin cancer, the approaches the team used to identify and block key activating proteins can be applied to find new treatments for similarly difficult-to-cure cancers.
Now the research team is looking to take their research to clinical trials to test out the STK19 inhibitor in humans, and hopefully, someday make it available as a targeted therapy to combat NRAS-driven melanomas.
In the meantime, Cui says that much work still needs to be done to not only create better and more precise treatments for patients suffering with melanoma, but also to alert vulnerable populations about the risk factors associated with the cancer.
“We need more monitoring for early diagnosis and full-body examinations for problematic spots,” says Cui, “and more proactive strategies for patients [at the highest risk of developing melanoma] to prevent cancer progression and metastasis.”
Learn more: Shutting Down Skin Cancer
The Latest on: Skin cancer
[google_news title=”” keyword=”skin cancer” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Skin cancer
- Skin Cancer: Why Are Men More Likely To Die From Melanoma Than Women?on April 27, 2024 at 3:55 am
Melanoma or skin cancer can affect both men and women However men are said to be more likely to succumb to the diseases Read to know why
- Netflix star, 26, diagnosed with skin cancer but had ‘no idea’ of warning sign for two yearson April 27, 2024 at 2:36 am
Too Hot to Handle star Harry Jowsey has revealed he has been diagnosed with skin cancer aged 26. The Aussie actor and TV personality took to his TikTok account late on Friday night with a post captioned ‘Please wear sunscreen’.
- Fact Check: Israel does not have the world’s second highest skin cancer rateon April 26, 2024 at 3:11 am
Data from 2022 on skin cancer rates worldwide show that Israel ranks 23rd, not highest “outside Australasia” or “second highest in the world”, contrary to posts online tying a statistic from a 21-year-old newspaper report to a narrative that people in Israel are not native to their region.
- Is Skin Cancer Itchy?on April 21, 2024 at 10:00 am
Itchiness can be a sign of skin cancer. The three most common types of skin cancer could cause itching. However, other common conditions itch too.
via Bing News